Assessing IQVIA Hldgs: Insights From 7 Financial Analysts
Across the recent three months, 7 analysts have shared their insights on IQVIA Hldgs (NYSE:IQV), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for IQVIA Hldgs, presenting an average target of $210.14, a high estimate of $235.00, and a low estimate of $180.00. This upward trend is evident, with the current average reflecting a 15.55% increase from the previous average price target of $181.86.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive IQVIA Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Windley | Jefferies | Raises | Buy | $225.00 | $195.00 |
| Ann Hynes | Mizuho | Raises | Outperform | $225.00 | $190.00 |
| Dan Leonard | UBS | Raises | Buy | $225.00 | $185.00 |
| Jailendra Singh | Truist Securities | Raises | Buy | $235.00 | $209.00 |
| Luke Sergott | Barclays | Raises | Equal-Weight | $185.00 | $165.00 |
| Eric Coldwell | Baird | Raises | Neutral | $196.00 | $159.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $180.00 | $170.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to IQVIA Hldgs. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IQVIA Hldgs compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of IQVIA Hldgs's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of IQVIA Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on IQVIA Hldgs analyst ratings.
Delving into IQVIA Hldgs's Background
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Financial Insights: IQVIA Hldgs
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: IQVIA Hldgs's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 5.32%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IQVIA Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 6.62%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): IQVIA Hldgs's ROE excels beyond industry benchmarks, reaching 4.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): IQVIA Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: IQVIA Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.72, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.